Neurogen Corporation - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Neurogen Corporation. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Neurogen Corporation. The Group's principal activities are to discover and develop new drugs for the treatment of neurological, inflammatory, pain and metabolic disorders. Through its Accelerated Intelligent Drug Discovery (TM) platform, it discovers compounds that hit new potential drug targets, evaluates the utility of those targets and optimizes useful leads into new drug candidates. The Group has collaboration agreements with Aventis Pharmaceuticals for the discovery and research of CRF1 receptor-based drugs and collaboration agreement with Merck Sharp & Dohme Limited to research, develop, and commercialize small molecule medicines. It also has a technology transfer agreement with Pfizer Inc. for the licensing and transfer of the Group's proprietary technologies for the discovery of new drugs to Pfizer as well as collaboration agreements for the discovery of GABA-based drugs for anxiety and cognitive disorders.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report